Oncolytics Biotech Inc T.ONC

New Press Release - Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO

7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25%T-cell expansion data correlate with tumor response, providing important proof-of-conceptSAN DIEGO and CALGARY, AB, Oct. 23, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY),( Oncolytics) (TSX: ONC),...read article.

[Lesalpes29]

In Matt we trust! If we look at the markets reaction after two NR this morning. Matt where are the deal and multiple phase 3 announcement? GL 

[Azzak34]

Matt doesn't control the markets you silly goose. His job is to produce strong results, which he continues to do.  Communication has been poor but ONCY continues to show why they're going to get bought out. 

[Lesalpes29]

I love goose and moose! If you read my post I'am asking Matt to deliver DEAL and PHASE 3 as he said. Probably coming in the coming weeks and I wish it to you and me and Canadafan, Fox and others here that ge will do it! GL

[Azzak34]

Then just wait. All wording and data shows it's a done deal. All we're waiting for is the announcement. Stop spreading fud and anxiety, just wait. 

[Lesalpes29]

Probably buy more and wait! Not going to post here until deal or phase 3 announcement to enjoy it with all the very long shareholders here. Have a very good end of 2023! GL

[Noteable]

ONCY is the only company to offer a pancreatic cancer treatment that is targeting advanced or metastatic pancreatic cancer, in which the 1 year survival rate is only 10%. "Several biotech developers have been making strides against the deadly disease, including a new mRNA vaccine in the works from BioNTech SE (NASDAQ:BNTX), as well as promising drug-combo therapies from

[Noteable]

The ORR of 62% is close to triple the average ORR in mPC which have been reported in historical control trials, suggesting that pelareorep synergizes with PD-L1 inhibitors and standard-of-care chemotherapy in patients with advanced/metastatic pancreatic ductal adenocarcinoma. By comparison in October 2022, the FDA approved J&J multiple myeloma cancer drug with an ORR of 61.8

[Noteable]

ONCYs TCR (TiLs) biomarker data as been further validated ,as stated in ONCYs press release today: T-Cell Populations: Analysis of changes of T-cell clones and tumor-infiltrating lymphocytes (TILs) showed: Expansion of pre-existing and new T cell clones, including the expansion of TIL-specific clones A correlation between the expansion in the blood of TIL-specific clones and tumor

[Noteable]

Roche to acquire Telavant for $7.1b. On the strength of biomarker data in Riovants Phase2b study , Roche is very likely looking towards filing an Accelerated Approval with the FDA for Telavant. And so it may be the same happening with the acquisition of ONCY

[Noteable]

The global ulcerative colitis market was valued at $7.1 billion in 2020, and is projected to reach $10.8 billion by 2030. - so  growth in this market segment appears to have matured, yet Roche decided to acquire Telavant for $7.1billion, presumably in part, on the strength of biomarker data in Riovants Phase2b study. https://www.globenewswire.com/en/news-release/2023

[Noteable]

As already posted... ONCY is the only company to offer a pancreatic cancer treatment that is targeting advanced or metastatic pancreatic cancer, in which the 1 year survival rate is only 10%. The others have targeted the earlier and less aggressive stages of pancreatic cancer, where the 5 year survival rate is now around 12 %. "Several biotech developers have been making

[Noteable]

2021 vs 2023 results in ONCYs 1st Phase 1 pancreatic cancer study evaluating pelareorep in combination with pembrolizumab in advanced pancreatic cancer vs ONCYs GOBLET Phase 1/2 clinical trial evaluating pelareorep in combination with atezolizumab in advanced/metastatic pancreatic cancer.  https://d1io3yog0oux5.cloudfront.net

[Azzak34]

I just had to re-log in to my other account to post this. Azzak is Noteable???? You've never seen us in the same room together! 

[Azzak34]

Great post Noteable. We spent the extra time fine tuning Pela and turning it in to a breakthrough therapy. Guess it was worth it!! 

[Noteable]

Yes - and a potential Accelerated Approval for the pelareorep combination which could result in pelareorep + CPI becoming a new Standard of Care (SOC) in the treatment of advanced/metastatic pancreatic cancer,given the current unmet treatment need for pancreatic cancer, and in particular for this aggressive form of pancreatic cancer.